Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
作者信息
Papalexandri Apostolia, Saloum Riad, Touloumenidou Tasoula, Papathanasiou Maria, Lalayanni Chrysaygi, Baldoumi Eirini, Demosthenous Christos, Zerva Panagiota, Koutra Maria-Georgia, Athanasiadou Anastasia, Anagnostopoulos Achilles
机构信息
Haematology Department and BMT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece.
出版信息
Hemasphere. 2018 Nov 12;2(6):e157. doi: 10.1097/HS9.0000000000000157. eCollection 2018 Dec.
Abstract
摘要
相似文献
1
Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?既往深度分子反应稳定的慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的急变期：停药是否安全？
Hemasphere. 2018 Nov 12;2(6):e157. doi: 10.1097/HS9.0000000000000157. eCollection 2018 Dec.
2
Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.单家医疗机构真实世界临床实践中 CML 患者酪氨酸激酶抑制剂的停药情况。
BMC Cancer. 2018 Dec 12;18(1):1245. doi: 10.1186/s12885-018-5167-y.
3
TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.酪氨酸激酶抑制剂轮换诱导的Ph+慢性粒细胞白血病多耐药急变期持续深度分子反应
Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.
4
Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.探讨慢性髓性白血病患者停止使用酪氨酸激酶抑制剂的决策。
Oncologist. 2019 Sep;24(9):1253-1258. doi: 10.1634/theoncologist.2018-0831. Epub 2019 Apr 3.
5
Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.用于慢性髓性白血病患者个体化管理的分子技术
Biomol Detect Quantif. 2017 Feb 14;11:4-20. doi: 10.1016/j.bdq.2017.01.001. eCollection 2017 Mar.
6
The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.酪氨酸激酶抑制剂对慢性髓性白血病干细胞的影响及其停药意义。
Stem Cells Dev. 2019 Nov 15;28(22):1480-1485. doi: 10.1089/scd.2019.0117. Epub 2019 Oct 22.
7
NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.NCCN 指南更新：慢性髓性白血病治疗中停止 TKI 治疗。
J Natl Compr Canc Netw. 2019 May 1;17(5.5):611-613. doi: 10.6004/jnccn.2019.5013.
8
[Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].[慢性粒细胞白血病急粒变与急淋变骨髓细胞形态学、免疫表型、细胞遗传学特征及预后的差异分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):629-33. doi: 10.7534/j.issn.1009-2137.2014.03.010.
9
Residual Peripheral Blood CD26 Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.慢性髓性白血病患者在酪氨酸激酶抑制剂治疗期间及无治疗缓解期的残留外周血CD26白血病干细胞
Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.
10
The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.Fas相关磷酸酶1在慢性髓性白血病酪氨酸激酶抑制剂治疗期间白血病干细胞持续存在中的作用
Leukemia. 2016 Jul;30(7):1502-9. doi: 10.1038/leu.2016.66. Epub 2016 Mar 17.
引用本文的文献
1
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.酪氨酸激酶抑制剂在慢性髓性白血病中的停药：适应证标准和成功预测因素。
Am J Hematol. 2022 Aug;97(8):1075-1085. doi: 10.1002/ajh.26556. Epub 2022 Apr 12.
2
Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI.病例报告：TKI停药5年后的慢性髓性白血病急变期病例的多组学分析及CAR-T治疗
Front Oncol. 2021 Sep 21;11:739871. doi: 10.3389/fonc.2021.739871. eCollection 2021.
3
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.慢性髓性白血病患者无治疗缓解：LALNET 专家小组的建议。
Blood Adv. 2021 Dec 14;5(23):4855-4863. doi: 10.1182/bloodadvances.2020003235.
4
When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.何时停止慢性髓性白血病患者的 TKI 治疗以及如何随后进行随访。
Curr Treat Options Oncol. 2021 Apr 17;22(6):49. doi: 10.1007/s11864-021-00851-2.
5
[The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].《中国慢性髓性白血病诊断与治疗指南（2020年版）》
Zhonghua Xue Ye Xue Za Zhi. 2020 May 14;41(5):353-364. doi: 10.3760/cma.j.issn.0253-2727.2020.05.001.
6
Treatment-free remission in patients with chronic myeloid leukaemia.慢性髓性白血病患者无治疗缓解。
Nat Rev Clin Oncol. 2020 Aug;17(8):493-503. doi: 10.1038/s41571-020-0367-1. Epub 2020 May 6.
7
Prospects for achieving treatment-free remission in chronic myeloid leukaemia.慢性髓性白血病实现无需治疗的缓解的前景。
Br J Haematol. 2020 Aug;190(3):318-327. doi: 10.1111/bjh.16506. Epub 2020 Feb 14.
8
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.慢性髓性白血病治疗无缓解患者可测量残留病的谱系。
Leukemia. 2020 Apr;34(4):1052-1061. doi: 10.1038/s41375-019-0647-x. Epub 2019 Nov 25.
本文引用的文献
1
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.二线尼洛替尼治疗后慢性髓性白血病慢性期患者无治疗缓解：单组、2 期、开放标签研究结果。
Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20.
2
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗停药后，我如何处理慢性髓性白血病复发问题。
Br J Haematol. 2018 Jan;180(1):24-32. doi: 10.1111/bjh.14973. Epub 2017 Oct 19.
3
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.慢性期慢性髓性白血病患者一线使用尼洛替尼后无治疗缓解：ENESTfreedom研究结果
Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.
4
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.达沙替尼或尼罗替尼治疗慢性髓性白血病的停药：STOP 2G-TKI 研究的中期分析。
Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.
5
Moving treatment-free remission into mainstream clinical practice in CML.推动无治疗缓解进入 CML 的主流临床实践。
Blood. 2016 Jul 7;128(1):17-23. doi: 10.1182/blood-2016-01-694265. Epub 2016 Mar 24.
6
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.在停止伊马替尼治疗后疾病持续不可检测的慢性期慢性髓性白血病患者中，主要分子学反应缺失可作为重新开始酪氨酸激酶抑制剂治疗的触发因素。
J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.
7
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.伊马替尼治疗产生的选择压力导致伊马替尼停药试验的结果存在差异。
Haematologica. 2012 Oct;97(10):1553-61. doi: 10.3324/haematol.2012.062844. Epub 2012 Mar 14.
8
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.至少持续 2 年完全分子缓解的慢性髓性白血病患者停止伊马替尼治疗：前瞻性、多中心停止伊马替尼（STIM）试验。
Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.
9
Do we have to kill the last CML cell?我们是否必须杀死最后一个 CML 细胞？
Leukemia. 2011 Feb;25(2):193-200. doi: 10.1038/leu.2010.197. Epub 2010 Sep 16.
Zotero 插件